Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Not yet recruiting Phase 3 Interventional

Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial

ClinicalTrials.gov ID: NCT07935889

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07935889. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Stereotactic Advanced-Imaging Guided Radiotherapy for Glioblastoma (SAGA 2.0)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This clinical trial studies how well advanced imaging-guided standard dose versus (vs.) dose-intensified radiation therapy (RT) and dose-intensified accelerated RT works in treating patients with newly diagnosed glioblastoma. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. During dose-intensified RT, a higher dose than normal of radiation therapy is delivered over 6 weeks. During dose-intensified accelerated RT, the higher dose of radiation therapy is delivered over a shorter amount of time (2 weeks) than normal (6 weeks). Patients also undergo an advanced brain imaging positron emission tomography (PET)/computed tomography (CT) scan (using a radioactive drug called either FET or FDOPA) prior to RT to that may help doctors better plan the treatment. Dose-intensified and dose-intensified accelerated radiation therapy may be effective in treating patients with newly diagnosed glioblastoma. Giving dose-intensified RT or dose-intensified accelerated RT guided by advanced imaging may work better than standard dose RT in treating patients with newly diagnosed glioblastoma. IND Numbers: 61300, 140882, 176402, 154793, 167879

Study identification

NCT ID
NCT07935889
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Mayo Clinic
Other
Enrollment
292 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 10, 2026 (Estimated)
Primary completion
Nov 2, 2035 (Estimated)
Completion
Nov 2, 2035 (Estimated)
Last update posted
Nov 13, 2026

2026 – 2035

United States locations

U.S. sites
7
U.S. states
4
U.S. cities
7
Facility City State ZIP Site status
Mayo Clinic in Arizona Scottsdale Arizona 85259 —
Mayo Clinic in Florida Jacksonville Florida 32224-9980 —
Mayo Clinic Health System in Albert Lea Albert Lea Minnesota 56007 —
Mayo Clinic Health Systems-Mankato Mankato Minnesota 56001 —
Mayo Clinic in Rochester Rochester Minnesota 55905 —
Mayo Clinic Health System-Eau Claire Clinic Eau Claire Wisconsin 54701 —
Mayo Clinic Health System-Franciscan Healthcare La Crosse Wisconsin 54601 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07935889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 13, 2026 · Synced Nov 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.